Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo

Table 2 Demographic and clinical characteristics on admission of patients included in the analyses, by treatment group

	No EVD-specific treatment		MAb114		REGN-EB3		Remdesivir		ZMapp		Overall		p
	n	%	n	%	n	%	n	%	n	%	n	%	p
Age (mean ± SD)	30.19		26.90		28.42		30.87		28.41		29.82		0.230
Time from onset of illness to admission (days)	8.84 **		4.71		4.82		5.17		4.75		5.13		< 0.001
Gender													0.504
Female	35	63.6	127	59.1	141	58.0	101	60.5	53	51.0	457	58.3
Male	20	36.4	88	40.9	102	42.0	66	39.5	51	49.0	327	41.7
Total	55	100.0	215	100.0	243	100.0	167	100.0	104	100.0	784	100.0
Profession													0.019
Others	53	96.4	183	85.1	223	91.8	149	89.2	96	92.3	704	89.8
Health professionals	1	1.8	26	12.1	19	7.8	18	10.8	5	4.8	69	8.8
Butcher/religious leader	1	1.8	6	2.8	1	0.4	0	0.0	3	2.9	11	1.4
Total	55	100.0	215	100.0	243	100.0	167	100.0	104	100.0	784	100.0
Days from admission to initiation of specific treatment													0.003
Same day			149	69.6	147	60.7	101	60.5	81	78.6	478	65.8
Not de same day			65	30.4	95	39.3	66	39.5	22	21.4	248	34.2
Vaccine status*													0.008
Not received	27	81.8	88	44.4	127	54.0	86	54.8	63	61.2	391	53.9
Received	3	9.1	47	23.7	46	19.6	34	21.7	20	19.4	150	20.7
Unknown	3	9.1	63	31.8	62	26.4	37	23.6	20	19.4	185	25.5
Total	33	100.0	198	100.0	235	100.0	157	100.0	103	100.0	726	100.0
Patient status*													< 0.001
Alive	6	10.9	150	70.1	164	67.8	90	53.9	52	50.5	462	59.2
Deceased	49	89.1	64	29.9	78	32.2	77	46.1	51	49.5	319	40.8
Total	55	100.0	214	100.0	242	100.0	167	100.0	103	100.0	781	100.0

*: there was missing information; SD: standard deviation. **: The post hoc test indicated a significant difference between this group and the others

ISSN: 1743-422X